Cargando…

Comparing cost-utility of DMARDs in autoantibody-negative rheumatoid arthritis patients

OBJECTIVES: To evaluate the 1-year cost-effectiveness between three different initial treatment strategies in autoantibody-negative RA patients, according to 2010 criteria. METHODS: For this analysis we selected all RA patients within the intermediate probability stratum of the treatment in the Rott...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nathalie, Luurssen-Masurel, Mulligen, Van Elise, Maria, Weel Angelique Elisabeth Adriana, Wilhelmina, Hazes Johanna Maria, Pieter, de Jong Pascal Hendrik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Clinical Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8645278/ https://www.ncbi.nlm.nih.gov/pubmed/33725091 http://dx.doi.org/10.1093/rheumatology/keab251

Ejemplares similares

Correction to: Comparing cost-utility of DMARDs in autoantibody-negative rheumatoid arthritis patients
por: Luurssen-Masurel, Nathalie, et al.
Publicado: (2022)

The impact of different (rheumatoid) arthritis phenotypes on patients’ lives
por: Luurssen-Masurel, Nathalie, et al.
Publicado: (2020)

Correction to: The impact of different (rheumatoid) arthritis phenotypes on patients’ lives
por: Luurssen-Masurel, Nathalie, et al.
Publicado: (2022)

Tapering towards DMARD-free remission in established rheumatoid arthritis: 2-year results of the TARA trial
por: van Mulligen, Elise, et al.
Publicado: (2020)

Diagnostic performance of the ACR/EULAR 2010 criteria for rheumatoid arthritis and two diagnostic algorithms in an early arthritis clinic (REACH)
por: Alves, Celina, et al.
Publicado: (2011)

Factors that influence biological survival in rheumatoid arthritis: results of a real-world academic cohort from the Netherlands
por: van Mulligen, Elise, et al.
Publicado: (2021)

The number of risk factors for persistent disease determines the clinical course of early arthritis
por: Luurssen-Masurel, N, et al.
Publicado: (2021)

Doctors’ preferences in de-escalating DMARDs in rheumatoid arthritis: a discrete choice experiment
por: Kuijper, T. Martijn, et al.
Publicado: (2017)

Two-year cost effectiveness between two gradual tapering strategies in rheumatoid arthritis: cost-utility analysis of the TARA trial
por: van Mulligen, Elise, et al.
Publicado: (2020)

Response to: ‘TARA Study: a new perspective on tapering drugs in RA’ by Mishra et al
por: van Mulligen, Elise, et al.
Publicado: (2020)

Current and Emerging DMARDs for the Treatment of Rheumatoid Arthritis
por: Mysler, Eduardo, et al.
Publicado: (2021)

DMARD-free remission as novel treatment target in rheumatoid arthritis: A systematic literature review of achievability and sustainability
por: Verstappen, M, et al.
Publicado: (2020)

Prediction of disease relapses by multibiomarker disease activity and autoantibody status in patients with rheumatoid arthritis on tapering DMARD treatment
por: Rech, Juergen, et al.
Publicado: (2016)

New autoantibodies in early rheumatoid arthritis
por: Charpin, Caroline, et al.
Publicado: (2013)

Multidrug resistance proteins and DMARD efficacy in rheumatoid arthritis
por: Jansen, G, et al.
Publicado: (2004)

Treatment of Rheumatoid Arthritis with Biologic DMARDS (Rituximab and Etanercept)
por: Gashi, Afrim A., et al.
Publicado: (2014)

Delayed conventional DMARDs therapy is effective in Rheumatoid Arthritis
por: Ahsan, Tasnim, et al.
Publicado: (2017)

Risk for infections with glucocorticoids and DMARDs in patients with rheumatoid arthritis
por: Riley, Thomas R, et al.
Publicado: (2021)

Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity
por: Prawjaeng, Juthamas, et al.
Publicado: (2023)

Biomarkers to Predict DMARDs Efficacy and Adverse Effect in Rheumatoid Arthritis
por: Wei, Kai, et al.
Publicado: (2022)

Rheumatoid Arthritis and Malignancy: What Should We Do With DMARDs?
por: Jeon, Chan Hong
Publicado: (2022)

In vitro glucocorticoid sensitivity is associated with clinical glucocorticoid therapy outcome in rheumatoid arthritis
por: Quax, Rogier AM, et al.
Publicado: (2012)

Early DAS response after DMARD-start increases probability of achieving sustained DMARD-free remission in rheumatoid arthritis
por: Verstappen, M., et al.
Publicado: (2020)

The supplementary therapeutic DMARD role of low-dose glucocorticoids in rheumatoid arthritis
por: Cutolo, Maurizio, et al.
Publicado: (2014)

Healthcare professionals’ perceptions on barriers and facilitators to DMARD use in rheumatoid arthritis
por: Voshaar, M. J. H., et al.
Publicado: (2022)

Autoantibodies to BRAF, a new family of autoantibodies associated with rheumatoid arthritis
por: Charpin, Caroline, et al.
Publicado: (2010)

Assessments of the unmet need in the management of patients with rheumatoid arthritis: analyses from the NOR-DMARD registry
por: Olsen, Inge C, et al.
Publicado: (2019)

Biologic DMARDs and targeted synthetic DMARDs and the risk of all-cause mortality in rheumatoid arthritis: A systematic review and meta-analysis
por: Pang, Mengduan, et al.
Publicado: (2022)

Common Transcriptomic Effects of Abatacept and Other DMARDs on Rheumatoid Arthritis Synovial Tissue
por: Triaille, Clement, et al.
Publicado: (2021)

Identification of biomarkers in patients with rheumatoid arthritis responsive to DMARDs but with progressive bone erosion
por: Marasco, Emiliano, et al.
Publicado: (2023)

COVID-19 outcomes in patients with rheumatoid arthritis with biologic or targeted synthetic DMARDs
por: Tsai, Jih-Jin, et al.
Publicado: (2023)

Treatment expectations as a possible prognostic factor for DMARD response in rheumatoid arthritis: a prospective cohort study
por: Mucke, Johanna, et al.
Publicado: (2021)

Patient groups in Rheumatoid arthritis identified by deep learning respond differently to biologic or targeted synthetic DMARDs
por: Kalweit, Maria, et al.
Publicado: (2023)

Review of Routine Laboratory Monitoring for Patients with Rheumatoid Arthritis Receiving Biologic or Nonbiologic DMARDs
por: Rigby, William F. C., et al.
Publicado: (2017)

The risk of malignancy and its incidence in early rheumatoid arthritis patients treated with biologic DMARDs
por: Cho, Soo-Kyung, et al.
Publicado: (2017)

Risk of infection in postmenopausal women with rheumatoid arthritis and osteoporosis taking denosumab and bDMARDS
por: Mirzaei, Alireza, et al.
Publicado: (2021)

Prediction of sustained biologic and targeted synthetic DMARD-free remission in rheumatoid arthritis patients
por: Burkard, Theresa, et al.
Publicado: (2021)

Comparison of the efficacy and safety indicators of DMARDs for rheumatoid arthritis: A network meta-analysis
por: Wang, Zunlian, et al.
Publicado: (2021)

Safety and efficacy of newer biologics DMARDs in the management of rheumatoid arthritis: A systematic review
por: Zago, Basiru Ahmad, et al.
Publicado: (2020)

Treatment with biologic DMARDs may not adversely affect lung nodules in rheumatoid arthritis patients
por: Karadeniz, Hazan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7jg9oh3c8eso1oue3iupq594l7